S&P 500   3,354.53 (-0.93%)
DOW   29,088.25 (-0.89%)
QQQ   232.99 (-1.68%)
AAPL   319.25 (-1.35%)
FB   213.74 (-1.72%)
MSFT   182.59 (-2.50%)
GOOGL   1,506.57 (-1.20%)
AMZN   2,135.57 (-1.60%)
CGC   22.53 (+3.49%)
NVDA   304.89 (-3.12%)
BABA   216.35 (-2.61%)
MU   58.41 (-2.63%)
GE   12.51 (-0.79%)
AMD   56.82 (-3.53%)
T   38.44 (+0.00%)
ACB   1.69 (-1.17%)
F   8.03 (+0.38%)
NFLX   380.45 (-1.49%)
BAC   34.73 (+0.03%)
DIS   139.18 (-1.50%)
S&P 500   3,354.53 (-0.93%)
DOW   29,088.25 (-0.89%)
QQQ   232.99 (-1.68%)
AAPL   319.25 (-1.35%)
FB   213.74 (-1.72%)
MSFT   182.59 (-2.50%)
GOOGL   1,506.57 (-1.20%)
AMZN   2,135.57 (-1.60%)
CGC   22.53 (+3.49%)
NVDA   304.89 (-3.12%)
BABA   216.35 (-2.61%)
MU   58.41 (-2.63%)
GE   12.51 (-0.79%)
AMD   56.82 (-3.53%)
T   38.44 (+0.00%)
ACB   1.69 (-1.17%)
F   8.03 (+0.38%)
NFLX   380.45 (-1.49%)
BAC   34.73 (+0.03%)
DIS   139.18 (-1.50%)
S&P 500   3,354.53 (-0.93%)
DOW   29,088.25 (-0.89%)
QQQ   232.99 (-1.68%)
AAPL   319.25 (-1.35%)
FB   213.74 (-1.72%)
MSFT   182.59 (-2.50%)
GOOGL   1,506.57 (-1.20%)
AMZN   2,135.57 (-1.60%)
CGC   22.53 (+3.49%)
NVDA   304.89 (-3.12%)
BABA   216.35 (-2.61%)
MU   58.41 (-2.63%)
GE   12.51 (-0.79%)
AMD   56.82 (-3.53%)
T   38.44 (+0.00%)
ACB   1.69 (-1.17%)
F   8.03 (+0.38%)
NFLX   380.45 (-1.49%)
BAC   34.73 (+0.03%)
DIS   139.18 (-1.50%)
S&P 500   3,354.53 (-0.93%)
DOW   29,088.25 (-0.89%)
QQQ   232.99 (-1.68%)
AAPL   319.25 (-1.35%)
FB   213.74 (-1.72%)
MSFT   182.59 (-2.50%)
GOOGL   1,506.57 (-1.20%)
AMZN   2,135.57 (-1.60%)
CGC   22.53 (+3.49%)
NVDA   304.89 (-3.12%)
BABA   216.35 (-2.61%)
MU   58.41 (-2.63%)
GE   12.51 (-0.79%)
AMD   56.82 (-3.53%)
T   38.44 (+0.00%)
ACB   1.69 (-1.17%)
F   8.03 (+0.38%)
NFLX   380.45 (-1.49%)
BAC   34.73 (+0.03%)
DIS   139.18 (-1.50%)
Log in

NASDAQ:CTSO - Cytosorbents Stock Price, Forecast & News

$5.82
-0.02 (-0.34 %)
(As of 02/20/2020 01:00 PM ET)
Today's Range
$5.77
Now: $5.82
$5.95
50-Day Range
$3.77
MA: $4.66
$5.84
52-Week Range
$3.49
Now: $5.82
$8.61
Volume10,276 shs
Average Volume322,182 shs
Market Capitalization$188.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$0.54 per share

Profitability

Net Income$-17,210,000.00

Miscellaneous

Employees125
Market Cap$188.68 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.


Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

How were Cytosorbents' earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) released its quarterly earnings data on Tuesday, November, 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.08. The medical research company had revenue of $6.10 million for the quarter, compared to the consensus estimate of $6.49 million. Cytosorbents had a negative net margin of 87.79% and a negative return on equity of 165.00%. View Cytosorbents' Earnings History.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cytosorbents.

What guidance has Cytosorbents issued on next quarter's earnings?

Cytosorbents issued an update on its fourth quarter 2019 IntraDay earnings guidance on Tuesday, January, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.4-7.4 million, compared to the consensus revenue estimate of $6.71 million.

What price target have analysts set for CTSO?

3 brokerages have issued 12-month price targets for Cytosorbents' shares. Their forecasts range from $8.00 to $13.00. On average, they expect Cytosorbents' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 89.0% from the stock's current price. View Analyst Price Targets for Cytosorbents.

What is the consensus analysts' recommendation for Cytosorbents?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytosorbents.

What are Wall Street analysts saying about Cytosorbents stock?

Here are some recent quotes from research analysts about Cytosorbents stock:
  • 1. Maxim Group analysts commented, "Cytosorbents reported 4Q18 with $5.5M in product sales, up 7% from $5.1M in 3Q18 and 30% from $4.2M y/y. For the year, revenue was $22.5M, a new record for the company and the first time revenue exceeded $20M. The company reported net income of ($5.4M) and $22.4M in cash." (3/8/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of CytoSorbents and our 12-month price target of $15.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 12%; and 2) price-earnings multiple using 25x 2025 earnings estimate discounted at 12%. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (3/8/2019)

Has Cytosorbents been receiving favorable news coverage?

Headlines about CTSO stock have trended extremely negative on Thursday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytosorbents earned a daily sentiment score of -4.3 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Cytosorbents.

Who are some of Cytosorbents' key competitors?

What other stocks do shareholders of Cytosorbents own?

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the folowing people:
  • Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)
  • Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)
  • Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)
  • Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)
  • Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80)

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.70%), Sargent Investment Group LLC (0.82%), Sargent Investment Group LLC (0.72%), Raymond James & Associates (0.44%), Bank of New York Mellon Corp (0.37%) and Charles Schwab Investment Management Inc. (0.25%). Company insiders that own Cytosorbents stock include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.

Which institutional investors are selling Cytosorbents stock?

CTSO stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Sargent Investment Group LLC, Sargent Investment Group LLC, Bradley Foster & Sargent Inc. CT, Charles Schwab Investment Management Inc., New York State Common Retirement Fund, Victory Capital Management Inc. and Bank of America Corp DE. View Insider Buying and Selling for Cytosorbents.

Which institutional investors are buying Cytosorbents stock?

CTSO stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Winning Points Advisors LLC, Goldman Sachs Group Inc., UBS Group AG, Spark Investment Management LLC, Barclays PLC and Bank of New York Mellon Corp. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch and Phillip P Chan. View Insider Buying and Selling for Cytosorbents.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $5.82.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $188.68 million and generates $22.50 million in revenue each year. The medical research company earns $-17,210,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.View Additional Information About Cytosorbents.

What is Cytosorbents' official website?

The official website for Cytosorbents is http://www.cytosorbents.com/.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]


MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  405 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel